Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2001 Sep;54(9):693-8.
doi: 10.1136/jcp.54.9.693.

Optimising testing for phospholipid antibodies

M Helbert  1 , S Bodger, J Cavenagh, D D'Cruz, J M Thomas, P MacCallum
Affiliations
Meta-Analysis

Optimising testing for phospholipid antibodies

M Helbert et al. J Clin Pathol. 2001 Sep.

Abstract

Aim: To compare anticardiolipin (ACL) and anti-beta2 glycoprotein 1 (beta2gp1) enzyme linked immunosorbent assays (ELISAs) in the diagnosis of antiphospholipid syndrome (APS) and to incorporate these results into a meta-analysis of published data.

Method: Three representative commercial ACL ELISAs and an in house beta2gp1 assay were optimised and then assessed on 124 sera from normal donors, patients with infection, or patients with APS. A Medline search was screened for papers meeting defined criteria to conduct a meta-analysis. The performance of the assays used in this study was included.

Results: A non-quantitative ACL assay performed at least as well as the anti-beta2gp1 assay in the diagnosis of APS. Meta-analysis confirmed that neither assay is perfect, although the anti-beta2gp1 assay had a higher specificity and lower sensitivity than the ACL assay.

Conclusions: The pooled data suggest that the ACL assay is used to investigate thrombosis without overt underlying pathology and that the improved specificity of the anti-beta2gp1 assay is exploited where infection, connective tissue disease, or atheroma are present.

PubMed Disclaimer

Figures

None
Figure 1 Receiver operating characteristic curves for anticardiolipin (ALC) and anti-ß2 glycoprotein 1 (anti-ß2gp1) assays. Assays are: (A) non-quantitative total ACL, (B) quantitative total ACL, (C) IgG ACL, (D) IgM ACL, (E) IgG anti-ß2gp1, (F) IgM anti-ß2gp1.
None
Figure 2 Sensitivities (A) and specificities (B) for anticardiolipin (ACL) and anti-ß2 glycoprotein 1 (anti-ß2gp1) assays in individual reports and derived from pooled data.
See this image and copyright information in PMC

References

    1. Ann Clin Lab Sci. 1997 Jan-Feb;27(1):41-6 - PubMed
    1. Thromb Haemost. 1996 Aug;76(2):220-5 - PubMed
    1. Clin Exp Immunol. 1997 Aug;109(2):304-9 - PubMed
    1. J Rheumatol. 1998 Apr;25(4):667-74 - PubMed
    1. Lupus. 1998;7(3):159-63 - PubMed

Publication types